Search Press releases Keywords From To 31 Aug 2026 UCB Comes to Agreement with U.S. Government to Lower the Cost of Medicine and Strengthen U.S. Manufacturing Read More 31 Aug 2026 Transparency notification Wellington Management Group LLP Read More 30 Jul 2026 UCB Delivers Strong Results, Raises 2026 Guidance and Positions for Next Growth Phase Read More 8 Jul 2026 UCB presents latest data from its targeted generalized myasthenia gravis treatment portfolio at International Congress on Neuromuscular Diseases 2026 Read More 17 Jun 2026 UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI[®]▼ (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d) Read More 17 Jun 2026 UCB completes acquisition of Candid Therapeutics, strengthening next generation immunology pipeline Read More Pagination First page Previous page Previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Page 3 of 67 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe